Differentially expressed cytosolic proteins in human leukemia and lymphoma cell lines correlate with lineages and functions

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1774, Issue 9, 2007, Pages 1173-1183

  Gez, Swetlana ^a   Crossett, Ben ^a   Christopherson, Richard I ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cytosolic proteins; DIGE; Expression profile; Leukemia; Lymphoma

Indexed keywords

ACTIN BINDING PROTEIN; ALPHA TUBULIN; BETA TUBULIN; C1 TETRAHYDROFOLATE SYNTHASE; CALVASCULIN; CYTOPLASM PROTEIN; ELONGATION FACTOR 2; GUANINE NUCLEOTIDE BINDING PROTEIN; MYELOPEROXIDASE; NEURON SPECIFIC ENOLASE; NUCLEOPHOSMIN; PHOSPHOPROTEIN 32 FAMILY MEMBER A; PROTEIN DISULFIDE ISOMERASE; RAN SPECIFIC GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; RAS RELATED PROTEIN RAB 11B; STATHMIN; TRANSGELIN 2; UBIQUITIN CONJUGATING ENZYME E2 N; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CELL LINEAGE; CELL STRAIN HL 60; CONTROLLED STUDY; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOMA CELL LINE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAJI CELL;

CELL LINE, TUMOR; CELL LINEAGE; CYTOSKELETAL PROTEINS; CYTOSOL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION PROFILING; HL-60 CELLS; HUMANS; LEUKEMIA; LYMPHOMA; NEOPLASM PROTEINS; PHOSPHOPYRUVATE HYDRATASE; UBIQUITIN-CONJUGATING ENZYMES;

EID: 34548227757     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2007.06.011     Document Type: Article

References (97)

1. Voss T., Ahorn H., Haberl P., Dohner H., and Wilgenbus K. Correlation of clinical data with proteomics profiles in 24 patients with B-cell chronic lymphocytic leukemia. Int. J. Cancer 91 (2001) 180-186
2. Lee I.N., Chen C.H., Sheu J.C., Lee H.S., Huang G.T., Yu C.Y., Lu F.J., and Chow L.P. Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry. J. Proteome Res. 4 (2005) 2062-2069
3. Morita A., Miyagi E., Yasumitsu H., Kawasaki H., Hirano H., and Hirahara F. Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma. Proteomics 6 (2006) 5880-5890
4. Alfonso P., Nunez A., Madoz-Gurpide J., Lombardia L., Sanchez L., and Casal J.I. Proteomic expression analysis of colorectal cancer by two-dimensional differential gel electrophoresis. Proteomics 5 (2005) 2602-2611
5. Fujii K., Kondo T., Yamada M., Iwatsuki K., and Hirohashi S. Toward a comprehensive quantitative proteome database: protein expression map of lymphoid neoplasms by 2-D DIGE and MS. Proteomics 6 (2006) 4856-4876
6. Gallagher R., Collins S., Trujillo J., McCredie K., Ahearn M., Tsai S., Metzgar R., Aulakh G., Ting R., Ruscetti F., and Gallo R. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 54 (1979) 713-733
7. Dalton Jr. W.T., Ahearn M.J., McCredie K.B., Freireich E.J., Stass S.A., and Trujillo J.M. HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3. Blood 71 (1988) 242-247
8. Drexler H.G., Quentmeier H., MacLeod R.A., Uphoff C.C., and Hu Z.B. Leukemia cell lines: in vitro models for the study of acute promyelocytic leukemia. Leuk. Res. 19 (1995) 681-691
9. Liang J.C., Ning Y., Wang R.Y., Padilla-Nash H.M., Schrock E., Soenksen D., Nagarajan L., and Ried T. Spectral karyotypic study of the HL-60 cell line: detection of complex rearrangements involving chromosomes 5, 7, and 16 and delineation of critical region of deletion on 5q31.1. Cancer Genet. Cytogenet. 113 (1999) 105-109
10. Breitman T.R., Selonick S.E., and Collins S.J. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc. Natl. Acad. Sci. U. S. A. 77 (1980) 2936-2940
11. Collins S.J. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood 70 (1987) 1233-1244
12. Gao J., Luo X., Tang K., Li X., and Li G. Epstein-Barr virus integrates frequently into chromosome 4q, 2q, 1q and 7q of Burkitt's lymphoma cell line (Raji). J. Virol. Methods 136 (2006) 193-199
13. Troxell M.L., Bangs C.D., Cherry A.M., Natkunam Y., and Kong C.S. Cytologic diagnosis of Burkitt lymphoma. Cancer 105 (2005) 310-318
14. Nakao Y., Tsuboi S., Fujita T., Masaoka T., Morikawa S., and Watanabe S. Glucocorticoid receptors and terminal deoxynucleotidyl transferase activities in leukemic cells. Cancer 47 (1981) 1812-1817
15. Vishwanatha J.K., Salazar E., and Gopalakrishnan V.K. Absence of annexin I expression in B-cell non-Hodgkin's lymphomas and cell lines. BMC Cancer 4 (2004) 8
16. http://www.dsmz.de/human_and_animal_cell_lines.
17. Foley G.E., Lazarus H., Farber S., Uzman B.G., Boone B.A., and McCarthy R.E. Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 18 (1965) 522-529
18. Bertin R., Acquaviva C., Mirebeau D., Guidal-Giroux C., Vilmer E., and Cave H. CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 37 (2003) 44-57
19. O'Connor R., Cesano A., Kreider B.L., Lange B., Clark S.C., Nowell P.C., Finan J., Rovera G., and Santoli D. Growth factor-dependent differentiation along the myeloid and lymphoid lineages in an immature acute T lymphocytic leukemia. J. Immunol. 145 (1990) 3779-3787
20. Stacchini A., Aragno M., Vallario A., Alfarano A., Circosta P., Gottardi D., Faldella A., Rege-Cambrin G., Thunberg U., Nilsson K., and Caligaris-Cappio F. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk. Res. 23 (1999) 127-136
21. Gottardi D., Alfarano A., De Leo A.M., Stacchini A., Aragno M., Rigo A., Aragno M., Veneri D., Zanotti R., Pizzolo G., and Caligaris-Cappio F. In leukaemic CD5+ B cells the expression of BCL-2 gene family is shifted toward protection from apoptosis. Br. J. Haematol. 94 (1996) 612-618
22. Dohner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L., Dohner K., Bentz M., and Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343 (2000) 1910-1916
23. Alfarano A., Indraccolo S., Circosta P., Minuzzo S., Vallario A., Zamarchi R., Fregonese A., Calderazzo F., Faldella A., Aragno M., Camaschella C., Amadori A., and Caligaris-Cappio F. An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia. Blood 93 (1999) 2327-2335
24. Shin Y.K., Yoo B.C., Chang H.J., Jeon E., Hong S.H., Jung M.S., Lim S.J., and Park J.G. Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res. 65 (2005) 3162-3170
25. Rahman-Roblick R., Roblick U.J., Hellman U., Conrotto P., Liu T., Becker S., Hirschberg D., Jornvall H., Auer G., and Wiman K.G. p53 targets identified by protein expression profiling. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 5401-5406
26. Seike M., Kondo T., Fujii K., Yamada T., Gemma A., Kudoh S., and Hirohashi S. Proteomic signature of human cancer cells. Proteomics 4 (2004) 2776-2788
27. Fujii K., Kondo T., Yokoo H., Yamada T., Matsuno Y., Iwatsuki K., and Hirohashi S. Protein expression pattern distinguishes different lymphoid neoplasms. Proteomics 5 (2005) 4274-4286
28. Cussac D., Pichereaux C., Colomba A., Capilla F., Pont F., Gaits-Iacovoni F., Lamant L., Espinos E., Burlet-Schiltz O., Monsarrat B., Delsol G., and Payrastre B. Proteomic analysis of anaplastic lymphoma cell lines: identification of potential tumour markers. Proteomics 6 (2006) 3210-3222
29. Vaughn C.P., Crockett D.K., Lin Z., Lim M.S., and Elenitoba-Johnson K.S. Identification of proteins released by follicular lymphoma-derived cells using a mass spectrometry-based approach. Proteomics 6 (2006) 3223-3230
30. Balkhi M.Y., Trivedi A.K., Geletu M., Christopeit M., Bohlander S.K., Behre H.M., and Behre G. Proteomics of acute myeloid leukaemia: cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications. Oncogene 53 (2006) 7041-7058
31. Wagner B.A., Buettner G.R., Oberley L.W., Darby C.J., and Burns C.P. Myeloperoxidase is involved in H2O2-induced apoptosis of HL-60 human leukemia cells. J. Biol. Chem. 275 (2000) 22461-22469
32. Provost P., Doucet J., Stock A., Gerisch G., Samuelsson B., and Radmark O. Coactosin-like protein, a human F-actin-binding protein: critical role of lysine-75. Biochem. J. 359 (2001) 255-263
33. Cui J.W., Wang J., He K., Jin B.F., Wang H.X., Li W., Kang L.H., Hu M.R., Li H.Y., Yu M., Shen B.F., Wang G.J., and Zhang X.M. Two-dimensional electrophoresis protein profiling as an analytical tool for human acute leukemia classification. Electrophoresis 26 (2005) 268-279
34. Goto K., Endo H., and Fujiyoshi T. Cloning of the sequences expressed abundantly in established cell lines: identification of a cDNA clone highly homologous to S-100, a calcium binding protein. J. Biochem. (Tokyo) 103 (1988) 48-53
35. Jackson-Grusby L.L., Swiergiel J., and Linzer D.I. A growth-related mRNA in cultured mouse cells encodes a placental calcium binding protein. Nucleic Acids Res. 15 (1987) 6677-6690
36. Li Z.H., and Bresnick A.R. The S100A4 metastasis factor regulates cellular motility via a direct interaction with myosin-IIA. Cancer Res. 66 (2006) 5173-5180
37. Grum-Schwensen B., Klingelhofer J., Berg C.H., El-Naaman C., Grigorian M., Lukanidin E., and Ambartsumian N. Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer Res. 65 (2005) 3772-3780
38. Zhang S., Wang G., Liu D., Bao Z., Fernig D.G., Rudl P.S., and Barraclough R. The C-terminal region of S100A4 is important for its metastasis-inducing properties. Oncogene 24 (2005) 4401-4411
39. Mazzucchelli L. Protein S100A4: too long overlooked by pathologists?. Am. J. Pathol. 160 (2002) 7-13
40. Helfman D.M., Kim E.J., Lukanidin E., and Grigorian M. The metastasis associated protein S100A4: role in tumour progression and metastasis. Br. J. Cancer 92 (2005) 1955-1958
41. Wada H., Shirakawa S., Yamakado T., Ohkubo S., Tanaka T., Yamamoto T., and Hidaka H. S-100 antigen and calmodulin in human leukemic cells. Leuk. Res. 13 (1989) 65-69
42. Ng C.S., Lam T.K., Chan J.K., Hui P.K., Ng H.K., Szeto S.C., and Feng C.S. Juvenile chronic myeloid leukemia. A malignancy of S-100 protein-positive histiocytes. Am. J. Clin. Pathol. 90 (1988) 575-582
43. Carbone A., Manconi R., Poletti A., Colombatti A., Tirelli U., and Volpe R. S-100 protein, fibronectin, and laminin immunostaining in lymphomas of follicular center cell origin. Cancer 58 (1986) 2169-2176
44. Claudio J.O., Masih-Khan E., Tang H., Goncalves J., Voralia M., Li Z.H., Nadeem V., Cukerman E., Francisco-Pabalan O., Liew C.C., Woodgett J.R., and Stewart A.K. A molecular compendium of genes expressed in multiple myeloma. Blood 100 (2002) 2175-2186
45. Shen J., Person M.D., Zhu J., Abbruzzese J.L., and Li D. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res. 64 (2004) 9018-9026
46. Chen C.Y., Jia J.H., Zhang M.X., Meng Y.S., Kong D.X., Pan X.L., and Yu X.P. Proteomic analysis on multi-drug resistant cells HL-60/DOX of acute myeloblastic leukemia. Chin. J. Physiol. 48 (2005) 115-120
47. Seo S.B., McNamara P., Heo S., Turner A., Lane W.S., and Chakravarti D. Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. Cell 104 (2001) 119-130
48. von Lindern M., van Baal S., Wiegant J., Raap A., Hagemeijer A., and Grosveld G. Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3′ half to different genes: characterization of the set gene. Mol. Cell Biol. 12 (1992) 3346-3355
49. Li M., Makkinje A., and Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J. Biol. Chem. 271 (1996) 11059-11062
50. Fink T.M., Vaesen M., Kratzin H.D., Lichter P., and Zimmer M. Localization of the gene encoding the putative human HLA class II associated protein (PHAPI) to chromosome 15q22.3-q23 by fluorescence in situ hybridization. Genomics 29 (1995) 309-310
51. Bischoff F.R., Krebber H., Kempf T., Hermes I., and Ponstingl H. Human RanGTPase-activating protein RanGAP1 is a homologue of yeast Rna1p involved in mRNA processing and transport. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 1749-1753
52. Kalab P., Pu R.T., and Dasso M. The ran GTPase regulates mitotic spindle assembly. Curr. Biol. 9 (1999) 481-484
53. Nishimoto T. A new role of ran GTPase. Biochem. Biophys. Res. Commun. 262 (1999) 571-574
54. Di Matteo G., Fuschi P., Zerfass K., Moretti S., Ricordy R., Cenciarelli C., Tripodi M., Jansen-Durr P., and Lavia P. Transcriptional control of the Htf9-A/RanBP-1 gene during the cell cycle. Cell Growth Differ. 6 (1995) 1213-1224
55. Stein M.P., Dong J., and Wandinger-Ness A. Rab proteins and endocytic trafficking: potential targets for therapeutic intervention. Adv. Drug Deliv. Rev. 55 (2003) 1421-1437
56. Yang M., Chen T., Han C., Li N., Wan T., and Cao X. Rab7b, a novel lysosome-associated small GTPase, is involved in monocytic differentiation of human acute promyelocytic leukemia cells. Biochem. Biophys. Res. Commun. 318 (2004) 792-799
57. Hingorani K., Szebeni A., and Olson M.O. Mapping the functional domains of nucleolar protein B23. J. Biol. Chem. 275 (2000) 24451-24457
58. Okuda M., Horn H.F., Tarapore P., Tokuyama Y., Smulian A.G., Chan P.K., Knudsen E.S., Hofmann I.A., Snyder J.D., Bove K.E., and Fukasawa K. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 103 (2000) 127-140
59. Colombo E., Marine J.C., Danovi D., Falini B., and Pelicci P.G. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat. Cell Biol. 4 (2002) 529-533
60. Grisendi S., Mecucci C., Falini B., and Pandolfi P.P. Nucleophosmin and cancer. Nat. Rev., Cancer 6 (2006) 493-505
61. Mendes-da-Silva P., Moreira A., Duro-da-Costa J., Matias D., and Monteiro C. Frequent loss of heterozygosity on chromosome 5 in non-small cell lung carcinoma. Mol. Pathol. 53 (2000) 184-187
62. Falini B., Mecucci C., Tiacci E., Alcalay M., Rosati R., Pasqualucci L., Starza R., Diverio D., Diverio E., Colombo E., Pasqualucci L., Santucci A., Bigerna B., Pacini R., Pucciarini A., Liso A., Vignetti M., Fazi P., Meani N., Pettirossi V., Saglio G., Mandelli F., Lo-Coco F., Pelicci P.G., and Martelli M.F. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N. Engl. J. Med. 352 (2005) 254-266
63. Chou W.C., Tang J.L., Lin L.I., Yao M., Tsay W., Chen C.Y., Wu S.J., Huang C.F., Chiou R.J., Tseng M.H., Lin D.T., Lin K.H., Chen Y.C., and Tien H.F. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res. 66 (2006) 3310-3316
64. Krajinovic M., Lemieux-Blanchard E., Chiasson S., Primeau M., Costea I., and Moghrabi A. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 4 (2004) 66-72
65. Chen J., Kyte C., Valcin M., Chan W., Wetmur J.G., Selhub J., Hunter D.J., and Ma J. Polymorphisms in the one-carbon metabolic pathway, plasma folate levels and colorectal cancer in a prospective study. Int. J. Cancer 110 (2004) 617-620
66. Zou L., Wu Y., Pei L., Zhong D., Gen M., Zhao T., Wu J., Ni B., Mou Z., Han J., Chen Y., and Zhi Y. Identification of leukemia-associated antigens in chronic myeloid leukemia by proteomic analysis. Leuk. Res. 29 (2005) 1387-1391
67. Neben K., Tews B., Wrobel G., Hahn M., Kokocinski F., Giesecke C., Krause U., Ho A.D., Kramer A., and Lichter P. Gene expression patterns in acute myeloid leukemia correlate with centrosome aberrations and numerical chromosome changes. Oncogene 23 (2004) 2379-2384
68. Burkhart C.A., Kavallaris M., and Band Horwitz S. The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim. Biophys. Acta 1471 (2001) O1-O9
69. Alli E., Bash-Babula J., Yang J.M., and Hait W.N. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res. 62 (2002) 6864-6869
70. Antonucci F., Chilosi M., Parolini C., Hamdan M., Astner H., and Righetti P.G. Two-dimensional molecular profiling of mantle cell lymphoma. Electrophoresis 24 (2003) 2376-2385
71. Melhem R.F., Zhu X.X., Hailat N., Strahler J.R., and Hanash S.M. Characterization of the gene for a proliferation-related phosphoprotein (oncoprotein 18) expressed in high amounts in acute leukemia. J. Biol. Chem. 266 (1991) 17747-17753
72. Jeha S., Luo X.N., Beran M., Kantarjian H., and Atweh G.F. Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells. Cancer Res. 56 (1996) 1445-1450
73. Zhang D., Tai Y.C., Wong C.H., Tai L.K., Koay E.S., and Chen C.S. Molecular response of leukemia HL-60 cells to genistein treatment, a proteomics study. Leuk. Res. 1 (2007) 75-82
74. Nakashima D., Uzawa K., Kasamatsu A., Koike H., Endo Y., Saito K., Hashitani S., Numata T., Urade M., and Tanzawa H. Protein expression profiling identifies maspin and stathmin as potential biomarkers of adenoid cystic carcinoma of the salivary glands. Int. J. Cancer 118 (2006) 704-713
75. Stanier P., Abu-Hayyeh S., Murdoch J.N., Eddleston J., and Copp A.J. Paralogous sm22alpha (Tagln) genes map to mouse chromosomes 1 and 9: further evidence for a paralogous relationship. Genomics 51 (1998) 144-147
76. Hoffrogge R., Mikkat S., Scharf C., Beyer S., Christoph H., Pahnke J., Mix E., Berth M., Uhrmacher A., Zubrzycki I.Z., Miljan E., Volker U., and Rolfs A. 2-DE proteome analysis of a proliferating and differentiating human neuronal stem cell line (ReNcell VM). Proteomics 6 (2006) 1833-1847
77. Woo J.H., and Kim H.S. Phosphorylation of eukaryotic elongation factor 2 can be regulated by phosphoinositide 3-kinase in the early stages of myoblast differentiation. Mol. Cells 21 (2006) 294-301
78. Zelivianski S., Liang D., Chen M., Mirkin B.L., and Zhao R.Y. Suppressive effect of elongation factor 2 on apoptosis induced by HIV-1 viral protein R. Apoptosis 11 (2006) 377-388
79. Alaiya A., Roblick U., Egevad L., Carlsson A., Franzen B., Volz D., Huwendiek S., Linder S., and Auer G. Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma. Anal. Cell. Pathol. 21 (2000) 1-9
80. Rosenwald I.B. The role of translation in neoplastic transformation from a pathologist's point of view. Oncogene 23 (2004) 3230-3247
81. Caraglia M., Budillon A., Vitale G., Lupoli G., Tagliaferri P., and Abbruzzese A. Modulation of molecular mechanisms involved in protein synthesis machinery as a new tool for the control of cell proliferation. Eur. J. Biochem. 267 (2000) 3919-3936
82. Meric F., and Hunt K.K. Translation initiation in cancer: a novel target for therapy. Mol. Cancer Ther. 1 (2002) 971-979
83. Yonemura S., Tsukita S., and Tsukita S. Direct involvement of ezrin/radixin/moesin (ERM)-binding membrane proteins in the organization of microvilli in collaboration with activated ERM proteins. J. Cell Biol. 145 (1999) 1497-1509
84. Kobel M., Gradhand E., Zeng K., Schmitt W.D., Kriese K., Lantzsch T., Wolters M., Dittmer J., Strauss H.G., Thomssen C., and Hauptmann S. Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma. Int. J. Gynecol. Pathol. 25 (2006) 121-130
85. Zhang Y., Hu M.Y., Wu W.Z., Wang Z.J., Zhou K., Zha X.L., and Liu K.D. The membrane-cytoskeleton organizer ezrin is necessary for hepatocellular carcinoma cell growth and invasiveness. J. Cancer Res. Clin. Oncol. 132 (2006) 685-697
86. Verrills N.M., Liem N.L., Liaw T.Y., Hood B.D., Lock R.B., and Kavallaris M. Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia-an in vivo study. Proteomics 6 (2006) 1681-1694
87. Kaul S.C., Mitsui Y., Komatsu Y., Reddel R.R., and Wadhwa R. A highly expressed 81 kDa protein in immortalized mouse fibroblast: its proliferative function and identity with ezrin. Oncogene 13 (1996) 1231-1237
88. Ebert W., Muley T., and Drings P. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?. Anticancer Res. 16 (1996) 2161-2168
89. van den Doel E.M., Roholl P.J., Rijksen G., van Veelen C.W., and Staal G.E. Enolase isoenzymes in human cerebral metastasis. Tumour Biol. 10 (1989) 164-172
90. Fujiwara H., Arima N., Ohtsubo H., Matsumoto T., Kukita T., Kawada H., Imaizumi R., Ozaki A., Matsushita K., and Tei C. Clinical significance of serum neuron-specific enolase in patients with adult T-cell leukemia. Am. J. Hematol. 71 (2002) 80-84
91. Durany N., Joseph J., Jimenez O.M., Climent F., Fernandez P.L., Rivera F., and Carreras J. Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase, creatine kinase and enolase activity and isoenzymes in breast carcinoma. Br. J. Cancer 82 (2000) 20-27
92. Takashi M., Haimoto H., Tanaka J., Murase T., and Kato K. Evaluation of gamma-enolase as a tumor marker for renal cell carcinoma. J. Urol. 141 (1989) 830-834
93. Nemeth J., Galian A., Mikol J., Cochand-Priollet B., Wassef M., and Lavergne A. Neuron-specific enolase and malignant lymphomas (23 cases). Virchows Arch., A Pathol. Anat. Histopathol. 412 (1987) 89-93
94. Massarelli G., Onida G.A., Piras M.A., Marras V., Mura A., and Tanda F. Neuron-specific enolase (gamma enolase, gamma-gamma dimer) expression in Hodgkin's disease and large cell lymphomas. Anticancer Res. 19 (1999) 3933-3938
95. Syed N.A., Andersen P.L., Warrington R.C., and Xiao W. Uev1A, a ubiquitin conjugating enzyme variant, inhibits stress-induced apoptosis through NF-kappaB activation. Apoptosis 12 (2006) 2147-2157
96. Chen L., and Madura K. Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res. 65 (2005) 5599-5606
97. Mo Y.Y., Yu Y., Theodosiou E., Rachel Ee P.L., and Beck W.T. A role for Ubc9 in tumorigenesis. Oncogene 24 (2005) 2677-2683